Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?

How do you ask a woman to be the last woman to suffer for an unlikely, non-lethal recurrence?

For women with low-risk breast cancer, endocrine therapy does not improve survival and is less effective at decreasing recurrences—we saw this in NSABP B-21. Yet it causes years of suffering: arthralgia, ho...

Given that there are no cancer control outcomes (local control) and the follow-up is short from EUROPA, I would say no.

However, I do talk to patients eligible for omission of RT about this option and the data that are available. while it's an old trial, B21 showed RT drastically reduced LR as compar...